AbbVie Director Susan E. Quaggin Acquires Stock Equivalent Units via Fee Deferral
AbbVie Inc.
Subscribe to track ABBV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
=== SEC FORM 4: AbbVie Inc. (ABBV) ===
Insider: Quaggin Susan E
Role: Director
Date: 2026-09-30
Type: Acquisition (Stock Equivalent Units)
Amount: 59 units @ $261.59
Total Value: $15,433.81
Ending Bal: 918 units
Significance: Low (Routine Director Compensation Deferral)
Comprehensive Analysis
Overview & Context
On October 2, 2026, AbbVie Inc. director Susan E. Quaggin filed a Form 4 reporting the acquisition of 59 Stock Equivalent Units on September 30, 2026. The transaction was priced at $261.59 per unit, representing a total value of approximately $15,433.81.
Transaction Details
- Security: Stock Equivalent Units (convertible 1-to-1 into AbbVie Common Stock upon distribution)
- Transaction Code: 'A' (Grant, award, or other acquisition)
- Nature: Director fees credited to an unfunded book account under AbbVie's director compensation plan.
- Post-Transaction Holdings: 918 stock equivalent units (which includes units credited via dividend reinvestment).
Market & Trading Significance
This transaction carries Low informational significance for investors. It represents routine director fee crediting in the form of phantom or stock equivalent units rather than an open-market discretionary purchase or sale. Distributions from this account commence upon retirement from the board or reaching age 65.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.